GB9620892D0 - Methods of treating RAF mediated diseases - Google Patents

Methods of treating RAF mediated diseases

Info

Publication number
GB9620892D0
GB9620892D0 GBGB9620892.1A GB9620892A GB9620892D0 GB 9620892 D0 GB9620892 D0 GB 9620892D0 GB 9620892 A GB9620892 A GB 9620892A GB 9620892 D0 GB9620892 D0 GB 9620892D0
Authority
GB
United Kingdom
Prior art keywords
methods
mediated diseases
raf mediated
treating raf
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
GBGB9620892.1A
Other versions
GB2306108A (en
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9602867.5A external-priority patent/GB9602867D0/en
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of GB9620892D0 publication Critical patent/GB9620892D0/en
Publication of GB2306108A publication Critical patent/GB2306108A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
GB9620892A 1995-10-13 1996-10-07 Treatment of Raf-mediated cancers with imidazole derivatives Withdrawn GB2306108A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52195P 1995-10-13 1995-10-13
GBGB9602867.5A GB9602867D0 (en) 1996-02-13 1996-02-13 Methods of treating raf mediated diseases

Publications (2)

Publication Number Publication Date
GB9620892D0 true GB9620892D0 (en) 1996-11-27
GB2306108A GB2306108A (en) 1997-04-30

Family

ID=26308669

Family Applications (1)

Application Number Title Priority Date Filing Date
GB9620892A Withdrawn GB2306108A (en) 1995-10-13 1996-10-07 Treatment of Raf-mediated cancers with imidazole derivatives

Country Status (1)

Country Link
GB (1) GB2306108A (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU742293B2 (en) 1997-06-12 2001-12-20 Aventis Pharma Limited Imidazolyl-cyclic acetals
AU8154998A (en) * 1997-06-19 1999-01-04 Smithkline Beecham Corporation Novel aryloxy substituted pyrimidine imidazole compounds
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6174901B1 (en) 1998-12-18 2001-01-16 Amgen Inc. Substituted pyridine and pyridazine compounds and methods of use
AU4556800A (en) * 1999-04-27 2000-11-10 Smithkline Beecham Plc Novel treatment
JP2003525936A (en) 2000-03-06 2003-09-02 スミスクライン ビーチャム パブリック リミテッド カンパニー Imidazole derivatives as RAF kinase inhibitors
GB0005357D0 (en) * 2000-03-06 2000-04-26 Smithkline Beecham Plc Compounds
DK1318992T3 (en) * 2000-09-21 2005-11-21 Smithkline Beecham Plc Imidazole derivatives as Raf kinase inhibitors
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
GB0121490D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Ciompounds
US7446106B2 (en) 2001-09-05 2008-11-04 Smithkline Beecham Plc Pyridylfurans and pyrroles as Raf kinase inhibitors
GB0121488D0 (en) 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
UA80295C2 (en) 2002-09-06 2007-09-10 Biogen Inc Pyrazolopyridines and using the same
US7569593B2 (en) * 2003-10-02 2009-08-04 Irm Llc Compounds and compositions as protein kinase inhibitors
US8546404B2 (en) 2005-12-13 2013-10-01 Merck Sharp & Dohme Compounds that are ERK inhibitors
ES2353437T3 (en) 2006-02-16 2011-03-02 Schering Corporation PIRROLIDINE DERIVATIVES AS ERK INHIBITORS.
AU2008281543A1 (en) 2007-08-01 2009-02-05 Pfizer Inc. Pyrazole compounds and their use as Raf inhibitors
NZ587504A (en) 2008-02-21 2012-09-28 Merck Sharp & Dohme Benzopyrazole derivatives as ERK inhibitors
US8242260B2 (en) * 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
WO2013096642A1 (en) * 2011-12-23 2013-06-27 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
UY36294A (en) 2014-09-12 2016-04-29 Novartis Ag COMPOUNDS AND COMPOSITIONS AS QUINASA INHIBITORS
EP3313420B1 (en) 2015-06-25 2024-03-13 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
EP3429603B1 (en) 2016-03-15 2021-12-29 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA945363B (en) * 1993-07-21 1995-03-14 Smithkline Beecham Corp Novel compounds

Also Published As

Publication number Publication date
GB2306108A (en) 1997-04-30

Similar Documents

Publication Publication Date Title
GB9620892D0 (en) Methods of treating RAF mediated diseases
PL324284A1 (en) Methods of treating diabetes
IL117417A0 (en) Method of treating cardiac inflammatory disease
ZA965088B (en) Methods of preventing or treating allergles
GB9617780D0 (en) Method of treatment
EP0735054A3 (en) Method of after treatment of modified polyolefins
GB9715295D0 (en) Novel method of treatment
GB9712866D0 (en) Novel method of treatment
GB9707693D0 (en) Novel method of treatment
ZA964247B (en) Method of treating chronic progressive vascular diseases
ZA971607B (en) Methods of treatment of allergic diseases
GB9715298D0 (en) Novel method of treatment
GB9715306D0 (en) Novel method of treatment
HUP9900138A3 (en) Method for treatment of wood element
GB9218027D0 (en) Novel method of treatment
GB9618341D0 (en) Method of treatment
ZA973988B (en) Method of treatment
GB9507825D0 (en) Method of treatment
EP0732938A4 (en) Method of treating intestinal disorders
GB9602867D0 (en) Methods of treating raf mediated diseases
GB9415902D0 (en) Method of treatment
GB9407335D0 (en) Method of treatment
GB9503200D0 (en) Methods of treatment
GB9414652D0 (en) Method of treatment
GB9523655D0 (en) Method of treatment

Legal Events

Date Code Title Description
WAP Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1)